GlaxoSmithKline Plc has revised upward its sales and adjusted operating profit guidance for 2022 – its first financial forecast since the demerger on 18 July of Haleon, its consumer products business. The new GSK is expected to produce sales growth of between 6%-8% this year, up from the previously forecast 5%-7%. Adjusted operating profit is expected to grow by between 13% to 15%, compared with a previous range of 12% to 14%.
